Umdlavuza we-Colorectal awudingi ukwelashwa ngamakhemikhali okuphelele ngemuva kwezinyanga eziyisithupha

Yabelana ngalokhu okuthunyelwe

According to the results of a unique global clinical trial study, some patients with stage III colon cancer who undergo surgical resection of their tumors and lymph nodes may not require standard six-month chemotherapy after chemotherapy. In contrast, for many low-risk patients, three months of chemotherapy does not significantly increase the rate of cancer recurrence and can prevent harmful side effects, including nerve damage caused by the chemotherapy drug oxaliplatin, or permanent pain, numbness and tingling .

This is a global trial launched in 2007 on the International Duration Assessment of Adjuvant Chemotherapy (IDEA). Six parallel Phase III trials in 12 countries in North America, Europe and Asia enrolled 12,834 eligible patients. Patients with stage III umdlavuza colon usually use FOLFOX or CAPOX chemotherapy for standard treatment after surgery. The researchers randomly assigned patients to treatment groups of three or six months.

Results: Three months of chemotherapy is not suitable for all patients. Instead, the data shows that the duration of chemotherapy should be determined based on the combination of drugs used and the individual characteristics of the patient ’s cancer: the degree of isisu deposition on the colon wall and the number of lymph nodes that the cancer has spread to. For low-risk patients-those with shallow tumors and affected lymph nodes-treatment with CAPOX for 3 months has been shown to be safe and effective, with little side effects, the same as the progression-free survival (PFS) of six months of treatment. However, in some cases, a six-month course of treatment is better for high-risk patients.

UDkt.Anthony Shields, onguprofesa eWayne State University School of Medicine, uthe empeleni, ngisebenzise le migomo emisha ezigulini ezinomdlavuza wamathumbu onobungozi obuncane, obonga isikhathi esiningi sokwelashwa futhi ezingavimbela nobuthi izinyanga eziyisithupha zomthelela we-chemotherapy. Cishe iziguli ezingama-400,000 emhlabeni wonke zibheka ukwelashwa okususelwa ku-oxaliplatin njengohlobo lwemithi yokwelashwa ngamakhemikhali ngemuva kokuhlinzwa, ngakho-ke lokhu okutholwe kuzoba nomthelela omkhulu.

Bhalisa ku-Newsletter yethu

Thola izibuyekezo futhi ungalokothi uphuthelwe ibhulogi evela kuCancerfax

Okuningi Okuzohlolwa

Ukuqonda i-BCMA: Ithagethi Yenguquko Ekulapheni Umdlavuza
Umdlavuza wegazi

Ukuqonda i-BCMA: Ithagethi Yenguquko Ekulapheni Umdlavuza

Isingeniso Emkhakheni oguqukayo njalo wokwelashwa kwe-oncological, ososayensi baphikelela befuna izinhloso ezingajwayelekile ezingakhulisa ukusebenza kokungenelela kuyilapho kunciphisa imiphumela engadingeki.

Dinga usizo? Ithimba lethu likulungele ukukusiza.

Sifisela ukululama okusheshayo kothandekayo wakho futhi oseduze.

Qala ingxoxo
Siku-inthanethi! Xoxa Nathi!
Skena ikhodi
Sawubona,

Siyakwamukela kuCancerFax!

ICancerFax iyinkundla yokuphayona ezinikele ekuxhumaniseni abantu ababhekene nomdlavuza oseqophelweni eliphezulu ngemithi yokwelapha yamangqamuzana efana ne-CAR T-Cell therapy, ukwelashwa kwe-TIL, nezivivinyo zomtholampilo emhlabeni wonke.

Sazise ukuthi yini esingakwenzela yona.

1) Ukwelashwa komdlavuza phesheya?
2) Ukwelashwa kwe-CAR T-Cell
3) Umuthi wokugomela umdlavuza
4) Ukubonisana ngevidiyo eku-inthanethi
5) Ukwelashwa kweProton